{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:18:41Z","timestamp":1790047121085,"version":"4.0.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.drup.2020.100733","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T02:13:57Z","timestamp":1603505637000},"page":"100733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["COVID-19 update: The race to therapeutic development"],"prefix":"10.1016","volume":"53","author":[{"given":"Julianne D.","family":"Twomey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis Q.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancy","family":"Nalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2020.100733_bib0005","series-title":"Prellis Biologics Pursues Bioprinted Lymph Nodes for Production of COVID-19 Antibodies","author":"3DPrint","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.drup.2020.100733_bib0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2020-0035","article-title":"COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics","volume":"11","author":"Amawi","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drup.2020.100733_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100721","article-title":"Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses","author":"Artese","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2020.100733_bib0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11239-020-02162-z","article-title":"The association between treatment with heparin and survival in patients with Covid-19","volume":"50","author":"Ayerbe","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drup.2020.100733_bib0030","series-title":"Developing Respiratory Therapeutics for Prophylaxis and Treatment","author":"Balfour","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0040","article-title":"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial","author":"Bian","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.drup.2020.100733_bib0045","series-title":"Plasma Gelsolin to Protect Tissue\/Organs in Severe Coronavirus Infection Without Compromising Pathogen Response","author":"Bioaegis Therapeutics","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0050","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2020.100733_bib0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0060","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc3545","article-title":"Type III interferons disrupt the lung epithelial barrier upon viral recognition","author":"Broggi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drup.2020.100733_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0070","series-title":"Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection","author":"BusinessWire","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0075","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01131","article-title":"Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation","volume":"11","author":"Cardone","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0085","series-title":"CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection","author":"Cel-Sci","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0090","series-title":"CEL-SCI To Develop LEAPS COVID-19 Immunotherapy in Collaboration With University of Georgia Center for Vaccines and Immunology","author":"Cel-Sci","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","article-title":"Kidney disease is associated with in-hospital death of patients with COVID-19","volume":"97","author":"Cheng","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.drup.2020.100733_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0110","series-title":"CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)","author":"Cytovia Therapeutics","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0115","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa236","article-title":"Recombinant human plasma gelsolin (rhu-pGSN) improves survival and attenuates lung injury in a murine model of multi-drug resistant Pseudomonas aeruginosa pneumonia","author":"DiNubile","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.drup.2020.100733_bib0120","article-title":"Can nebulised heparin reduce time to extubation in SARS CoV 2 the CHARTER study protocol","author":"Dixon","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.drup.2020.100733_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100719","article-title":"FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy","volume":"53","author":"Dro\u017cd\u017cal","year":"2020","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2020.100733_bib0130","series-title":"First COVID-19 Treatment Recommended for EU Authorisation","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0135","series-title":"Coronaviruses: Methods and Protocols","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015"},{"key":"10.1016\/j.drup.2020.100733_bib0140","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijid.2020.05.026","article-title":"Use of anakinra in severe COVID-19: a case report","volume":"96","author":"Filocamo","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.drup.2020.100733_bib0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0049-0172(10)80012-5","article-title":"Mechanism of action of hydroxychloroquine as an antirheumatic drug","volume":"23","author":"Fox","year":"1993","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.drup.2020.100733_bib0150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-Mediated inflammatory responses: from mechanisms to potential therapeutic tools","volume":"35","author":"Fu","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.drup.2020.100733_bib0155","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser B Phys."},{"key":"10.1016\/j.drup.2020.100733_bib0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0165","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0170","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drup.2020.100733_bib0175","series-title":"GT Biopharma Provides Update on Development of Trike(TM) Therapeutic for Treatment of COVID-19 Infection","author":"GT Biopharma","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0180","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.drup.2020.100733_bib0185","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drup.2020.100733_bib0190","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drup.2020.100733_bib0195","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02638-2017","article-title":"A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension","volume":"51","author":"Hemnes","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.drup.2020.100733_bib0200","series-title":"Food and Drug Administration (FDA) Revoke the Emergency Use Authorization (EUA) for Emergency Use of Oral Formulations of Chloroquine Phosphate (CQ) and Hydroxychloroquine Sulfate (HCQ)","author":"Hinton","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2020.100733_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101942","article-title":"Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients","volume":"63","author":"Hogan","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2020.100733_bib0215","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0220","article-title":"Effect of hydroxychloroquine in hospitalized patients with Covid-19","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0225","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100733_bib0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100733_bib0235","article-title":"Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2","author":"Huo","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.drup.2020.100733_bib0240","series-title":"Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19","author":"IgM Bio","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0245","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.drup.2020.100733_bib0250","article-title":"Novel ACE2-IgG1 fusions with improved activity against SARS-CoV2","author":"Iwanaga","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2020.100733_bib0255","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.jmb.2020.04.009","article-title":"Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop","volume":"432","author":"Jaimes","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drup.2020.100733_bib0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0265","series-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Johns Hopkins University","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drup.2020.100733_bib0275","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.drup.2020.100733_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0285","article-title":"Three big studies dim hopes that hydroxychloroquine can treat or prevent COVID-19","author":"Kupferschmidt","year":"2020","journal-title":"Sci. Mag."},{"key":"10.1016\/j.drup.2020.100733_bib0290","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2020.100733_bib0295","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-020-00662-x","article-title":"Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues","volume":"9","author":"Li","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.drup.2020.100733_bib0300","series-title":"Lilly Begins World\u2019s First Study of a Potential COVID-19 Antibody Treatment in Humans","author":"Lilly","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2014.06.013","article-title":"Accessory proteins of SARS-CoV and other coronaviruses","volume":"109","author":"Liu","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.drup.2020.100733_bib0315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2020.100733_bib0320","article-title":"Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Maes","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.drup.2020.100733_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100733_bib0330","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.drup.2020.100733_bib0335","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","volume":"383","author":"McMahon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14867-z","article-title":"B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction","volume":"11","author":"Minato","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2020.100733_bib0345","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2020.100733_bib0350","article-title":"COVID-19 pulmonary and olfactory dysfunctions: is the chemokine CXCL10 the common denominator?","author":"Oliviero","year":"2020","journal-title":"Neuroscientist"},{"key":"10.1016\/j.drup.2020.100733_bib0355","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2020.100733_bib0360","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02344-6","article-title":"Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant","volume":"18","author":"Pachetti","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0365","article-title":"Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results","author":"Pan","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.drup.2020.100733_bib0370","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drup.2020.100733_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105984","article-title":"Combating devastating COVID-19 by drug repurposing","author":"Pawar","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.drup.2020.100733_bib0380","series-title":"Special Approval for Emergency on Remdesivir for COVID-19","author":"Pharmaceuticals and Medical Devices Agency","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0385","series-title":"Pneumagen Ltd Announces Positive Anti\u2013Viral Activity for Novel Glycan Approach in Preventing COVID\u201319 Infections","author":"Pneumagen","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0390","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200653","article-title":"COVID-19 and emerging viral infections: the case for interferon lambda","volume":"217","author":"Prokunina-Olsson","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0395","doi-asserted-by":"crossref","first-page":"e02764","DOI":"10.1128\/mBio.02764-19","article-title":"Distinct roles for sialoside and protein receptors in coronavirus infection","volume":"11","author":"Qing","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.drup.2020.100733_bib0400","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","author":"RECOVERY Collaborative Group","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100733_bib0405","series-title":"Regeneron Announces Start of REGN-CoV2 Phase 3 COVID-19 Prevention Trial in Collaboration With National Institute of Allergy and Infectious Diseases (NIAID)","author":"Regeneron","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0410","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1172\/JCI46095","article-title":"Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection","volume":"121","author":"Renna","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2020.100733_bib0415","series-title":"Roche Provides an Update on the Phase III COVACTA Trial of Actemra\/RoActemra in Hospitalised Patients With Severe COVID-19 Associated Pneumonia","author":"Roche","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0420","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01229","article-title":"Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?","volume":"11","author":"Sallenave","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0425","series-title":"Sanofi and Regeneron Provide Update on Kevzara\u00ae (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients","author":"Sanofi","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0430","doi-asserted-by":"crossref","DOI":"10.1124\/mol.110.064261","article-title":"A small molecule oxocarbazate inhibitor of human cathepsin L blocks SARS and Ebola pseudotype virus infection into HEK 293T cells","author":"Shah","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2020.100733_bib0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2020.100733_bib0445","article-title":"No evidence for basigin\/CD147 as a direct SARS-CoV-2 spike binding receptor","author":"Shilts","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2020.100733_bib0450","series-title":"Vanderbilt, AstraZeneca Collaborate on New COVID-19 Antibody Research","author":"Snyder","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0455","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc5367","article-title":"HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19","volume":"5","author":"Spinelli","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0460","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.drup.2020.100733_bib0465","series-title":"COVID\u201019 Pandemic: Development of Recombinant Human ACE2 Fusion Protein Drug (SI\u2010F019) for the Treatment of Patients With Novel Coronavirus Pneumonia","author":"SystImmune","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0470","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0475","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drup.2020.100733_bib0480","series-title":"Celltrion Plans July COVID-19 Trial, Advances\u2019 super Antibody\u2019","author":"Taylor","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0485","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","article-title":"Mechanisms and enzymes involved in SARS coronavirus genome expression","volume":"84","author":"Thiel","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.drup.2020.100733_bib0490","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process","volume":"72","author":"Tran","year":"2019","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.drup.2020.100733_bib0495","series-title":"Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0500","series-title":"FDA Coronavirus Treatment Acceleration Program (CTAP)","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0505","series-title":"FDA Guidance for Industry - COVID-19: Developing Drugs and Biological Products for Treatment or Prevention","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0510","series-title":"Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0515","series-title":"COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0520","series-title":"FDA Approves First Treatment for COVID-19","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0525","series-title":"Dexamethasone Reduces Death in Hospitalised Patients With Severe Respiratory Complications of COVID-19","author":"University of Oxford","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0530","series-title":"This National Clinical Trial Aims to Identify Treatments That May Be Beneficial for People Hospitalised With Suspected or Confirmed COVID-19","author":"University of Oxford","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0535","series-title":"U.S. National Library of Medicine ClinicalTrials.gov","author":"US National Library of Medicine","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104351","article-title":"Emergence of genomic diversity and recurrent mutations in SARS-CoV-2, Infection","volume":"83","author":"van Dorp","year":"2020","journal-title":"Genetics and Evolution"},{"key":"10.1016\/j.drup.2020.100733_bib0545","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.drup.2020.100733_bib0550","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2020.100733_bib0555","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2020.100733_bib0560","series-title":"Phase I Start Marks First for anti-SARS-CoV-2 mAbs, First for AbCellera","author":"Wong","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0565","series-title":"Coronavirus \u2013 World Health Organization","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0570","series-title":"Coronavirus Disease (COVID-19): Dexamethasone","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0575","series-title":"\u201cSolidarity\u201d Clinical Trial for COVID-19 Treatments","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0580","series-title":"WHO Discontinues Hydroxychloroquine and lopinavir\/ritonavir Treatment Arms for COVID-19","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.drup.2020.100733_bib0585","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2020.04.031","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2020.100733_bib0590","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drup.2020.100733_bib0595","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2020.100733_bib0600","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.drup.2020.100733_bib0605","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2020.100733_bib0610","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1152\/ajplung.00094.2015","article-title":"Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function","volume":"309","author":"Yang","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.drup.2020.100733_bib0615","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drup.2020.100733_bib0620","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40261-020-00917-3","article-title":"Rational use of Tocilizumab in the treatment of novel coronavirus pneumonia","volume":"40","author":"Zhang","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.drup.2020.100733_bib0625","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2","volume":"16","author":"Zhou","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.drup.2020.100733_bib0630","series-title":"First Antibody Trial Launched in COVID-19 Patients","author":"Zimmer","year":"2020"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764620300637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764620300637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:59:34Z","timestamp":1761281974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764620300637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":126,"alternative-id":["S1368764620300637"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2020.100733","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 update: The race to therapeutic development","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2020.100733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100733"}}